4SC AG: 4SC expands avelumab supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer
Combination of domatinostat (HDAC inhibitor) and checkpoint inhibitor avelumab (anti-PD-L1 antibody) to be investigated in a second clinical study in Merkel cell carcinoma (MERKLIN 1 study) 4SC AG (4SC, FSE Prime Standard: VSC) today announced that it has entered into Mehr





